EMBARGOED FOR RELEASE: Sunday, Aug. 22, 2021, 5 a.m. Eastern Time
Note to journalists: Please report that this research will be presented at a meeting of the American Chemical Society.
Newswise — ATLANTA, Aug. 22, 2021 — Bacteria known as group B Streptococcus (GBS) are a common cause of blood infections, meningitis and stillbirth in newborns. Although GBS infections can often be treated or prevented with antibiotics, the bacteria are becoming increasingly resistant. Now, researchers have discovered that human milk oligosaccharides (HMOs) –– short strings of sugar molecules abundant in breast milk –– can help prevent GBS infections in human cells and tissues and in mice. Someday, HMOs might be able to replace antibiotics for treating infections in infants and adults, they say.
The researchers will present their results today at the fall meeting of the American Chemical Society (ACS). ACS Fall 2021 is a hybrid meeting being held virtually and in-person Aug. 22-26, and on-demand content will be available Aug. 30-Sept. 30. The meeting features more than 7,000 presentations on a wide range of science topics.
“Our lab has previously shown that mixtures of HMOs isolated from the milk of several different donor mothers have antimicrobial and antibiofilm activity against GBS,” says Rebecca Moore, who is presenting the work at the meeting. “We wanted to jump from these in vitro studies to see whether HMOs could prevent infections in cells and tissues from a pregnant woman, and in pregnant mice.” Moore is a graduate student in the labs of Steven Townsend, Ph.D., at Vanderbilt University and Jennifer Gaddy, Ph.D., at Vanderbilt University Medical Center.
According to the U.S. Centers for Disease Control and Prevention, about 2,000 babies in the U.S. get GBS each year, and 4-6% of them die from it. The bacteria are often transferred from mother to baby during labor and delivery. An expectant mother who tests positive for GBS is usually given intravenous antibiotics during labor to help prevent early-onset infections, which occur during the first week of life. Interestingly, the incidence of late-onset infections (which happen from one week to three months after birth) is higher in formula-fed than breastfed infants, which suggests that factors in breast milk could help protect against GBS. If so, the sugars could perhaps replace antibiotics, which, in addition to killing beneficial bacteria, are becoming less effective because of the rise in antibiotic resistance.
The researchers studied the effects of combined HMOs from several mothers on GBS infection of placental immune cells (called macrophages) and of the gestational membrane (the sac surrounding the fetus). “We found that HMOs were able to completely inhibit bacterial growth in both the macrophages and the membranes, so we very quickly turned to looking at a mouse model,” Moore says. They examined whether HMOs could prevent a GBS infection from spreading through the reproductive tract of pregnant mice. “In five different parts of the reproductive tract, we saw significantly decreased GBS infection with HMO treatment,” Moore notes.
To figure out which HMOs and other oligosaccharides have these antimicrobial effects and why, the researchers set up an artificial two-species microbiome with GBS and the beneficial Streptococcus salivarius species growing in a tissue culture plate, separated by a semi-permeable membrane. Then, the researchers added oligosaccharides that are commonly added to infant formula, called galacto-oligosaccharides (GOS), which are derived from plants. In the absence of the sugar, GBS suppressed the growth of the “good” bacteria, but GOS helped this beneficial species grow. “We concluded that GBS is producing lactic acid that inhibits growth, and then when we add the oligosaccharide, the beneficial species can use it as a food source to overcome this suppression,” Moore explains.
Somewhat surprisingly, the first HMOs they’ve tested in the system did not have this effect, but Townsend says it’s likely that one or more of the over 200 unique sugars in human milk will show activity in the artificial microbiome assay. The team plans to find out. The reason HMOs can treat and prevent GBS infection is likely two-fold, the researchers say: They act as an anti-adhesive by preventing pathogens from sticking to tissue surfaces and forming a biofilm, and they could act as a prebiotic by supporting the growth of good bacteria.
“HMOs have been around as long as humans have, and bacteria have not figured them out. Presumably, that’s because there are so many in milk, and they’re constantly changing during a baby’s development,” Townsend says. “But if we could learn more about how they work, it’s possible that we could treat different types of infections with mixtures of HMOs, and maybe one day this could be a substitute for antibiotics in adults, as well as babies.”
A recorded media briefing on this topic will be posted Monday, Aug. 23 at 9 a.m. Eastern time at www.acs.org/acsfall2021briefings.
The researchers acknowledge support and funding from the National Science Foundation.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and all its people. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive press releases from the American Chemical Society, contact [email protected].
Note to journalists: Please report that this research was presented at a meeting of the American Chemical Society.
Antimicrobial properties of human milk oligosaccharides in Group B Streptococcus
One of the most challenging problems facing the United States healthcare establishment is combatting hospital-acquired infections caused by bacteria that have developed antibiotic resistance. Several species of bacteria are responsible for this serious threat, including the Gram-positive, opportunistic bacterium Streptococcus agalactiae (Group B Streptococcus, GBS). Many strategies are currently employed in the clinic to prevent and treat GBS infections, one of which is combination therapy in which an adjuvant is administered along with the drug as this not only helps increase its efficacy, but also helps with the antibiotic resistance problem by lowering the dosages of the drugs required. In the Townsend Lab we are interested in exploring the putative antimicrobial activity conferred by human milk oligosaccharides (HMOs) and its ability to act as an adjuvant. In recent studies, a heterogeneous mixture of HMOs was found to possess antimicrobial and antibiofilm activity against GBS, as well as increase the efficacy of intracellular-targeting antibiotics through increased cell membrane permeability. Following up on the combination studies of HMOs with antibiotics in GBS, we expanded our studies to examine how HMOs will react when in coculture with commensal bacteria. We hypothesize that due to observed GBS growth inhibition in the presence of HMOs, cocultures with will allow HMOs to replace antibiotics in treatment of GBS and other multidrug resistant infections.
MEDIA CONTACTRegister for reporter access to contact details
ACS Fall 2021